Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Welcome and Introduction to Vi3C

Opportunities to Optimize Cancer Policies Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Nov

Today In Oncology

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Related Videos

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Welcome and Introduction to Vi3C

Opportunities to Optimize Cancer Policies Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Study Finds Personalized Risk Messages Had No Effect in Raising Colorectal Cancer Screening Participation

My 50 Years in Lymphoma: Lessons Learned?

Does Kidney Stone History Impact Survival Outcomes in Upper Tract Urothelial Carcinoma

Active Surveillance With Metformin vs Placebo in Low-Risk Prostate Cancer

Izalontamab Brengitecan in Recurrent or Metastatic Nasopharyngeal Carcinoma